As of September 30, 2026, Zymeworks Inc. carries a market capitalization of 1.90B, placing it among publicly traded companies globally. Its enterprise value stands at 1.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.90B |
| Enterprise Value | 1.85B |
Zymeworks Inc.'s next confirmed earnings release is scheduled for March 10, 2027.
| Earnings Date | 3/10/2027 |
As of September 30, 2026, Zymeworks Inc. has 71.72M shares outstanding.
| Shares Outstanding | 71.72M |
As of September 30, 2026, Zymeworks Inc. trades at a trailing price-to-earnings ratio of 45.05. The price-to-sales ratio is 7.34, and the price-to-book ratio stands at 7.36.
| PE Ratio | 45.05 |
| PS Ratio | 7.34 |
| PB Ratio | 7.36 |
| P/TBV Ratio | -6.57 |
| P/FCF Ratio | -17.54 |
| P/OCF Ratio | -17.43 |
As of September 30, 2026, Zymeworks Inc. trades at an EV/EBITDA multiple of 34.63 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 41.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.85B versus a market cap of 1.90B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 6.96 |
| EV / EBITDA | 34.63 |
| EV / EBIT | 41.96 |
As of September 30, 2026, Zymeworks Inc. maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.57, indicating elevated leverage, while an interest coverage ratio of 3.49 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.30 |
| Quick Ratio | 3.19 |
| Debt / Equity | 20.57 |
| Debt / EBITDA | 0.99 |
| Interest Coverage | 3.49 |
Over the twelve months ended September 30, 2026, Zymeworks Inc. posted a return on equity (ROE) of 14.98, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 5.50, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.01M in revenue per employee across its workforce of 264.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | 14.98 |
| Return on Assets (ROA) | 5.50 |
| Revenue Per Employee | 1.01M |
| Employee Count | 264.00 |
Over the twelve months ended September 30, 2026, Zymeworks Inc. recorded an income tax benefit of -3.19M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 40.12M, leaving 43.31M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -3.19M |
As of the close on November 16, 2026, Zymeworks Inc.'s stock has gained approximately 42.82% over the past 52 weeks. The 50-day moving average sits at 27.26, while the 200-day moving average is 25.54.
| 52-Week Price Change | 42.82% |
| 50-Day Moving Average | 27.26 |
| 200-Day Moving Average | 25.54 |
Over the twelve months ended September 30, 2026, Zymeworks Inc. generated 265.97M in revenue and converted that into 43.31M in net income, yielding earnings per share of 0.58. EBITDA reached 53.49M, while operating income came in at 44.22M.
| Revenue | 265.97M |
| Operating Income | 44.22M |
| Pretax Income | 40.12M |
| Net Income | 43.31M |
| EBITDA | 53.49M |
| EBIT | 44.15M |
| Earnings Per Share (EPS) | 0.58 |
As of September 30, 2026, Zymeworks Inc. holds 100.46M in cash and equivalents against 53.13M in total debt, resulting in a net debt position of -100.46M. Total book value stands at 258.25M, with working capital of 370.94M providing operational flexibility.
| Cash & Cash Equivalents | 100.46M |
| Total Debt | 53.13M |
| Net Debt | -100.46M |
| Equity (Book Value) | 258.25M |
| Book Value Per Share | 3.60 |
| Working Capital | 370.94M |
Zymeworks Inc. produced -111.96M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.01M in capital expenditures, free cash flow totaled -112.97M - equivalent to -1.53 per share.
| Operating Cash Flow | -111.96M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | -112.97M |
| FCF Per Share | -1.53 |
These figures cover the twelve months ended September 30, 2026. The operating margin of 16.63 and net profit margin of 16.28 provide insight into operational efficiency.
| Operating Margin | 16.63 |
| Pretax Margin | 15.09 |
| Profit Margin | 16.28 |
| EBITDA Margin | 20.11 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -5.70: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -23.42, meaning Zymeworks Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -23.42 |
| FCF Yield | -5.70 |
As of September 30, 2026, Zymeworks Inc. has an Altman Z-Score of 0.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.36 |